Screener
BridgeBio Pharma BBIO Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
| Total other expense, net | (60,599) | (65,236) |
| Net loss | (166,555) | (169,608) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,512 | 2,186 |
| Net loss attributable to common stockholders of BridgeBio | $(164,043) | $(167,422) |
| Net loss per share attributable to common stockholders of BridgeBio, basic and diluted | $(0.84) | $(0.88) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted | 194,789,897 | 190,145,253 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's net income?
- BridgeBio Pharma (BBIO) reported net income of -$166.56M in Q1 2026.
- How has BridgeBio Pharma's net income changed year-over-year?
- BridgeBio Pharma's net income increased by 1.8% year-over-year, from -$169.61M to -$166.56M.
- What is the long-term trend for BridgeBio Pharma's net income?
- Over 4 years (2021 to 2025), BridgeBio Pharma's net income has grown at a 5.7% compound annual growth rate (CAGR), from -$586.45M to -$732.94M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about BridgeBio Pharma's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude